Detalhe da pesquisa
1.
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
N Engl J Med
; 388(19): 1739-1754, 2023 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37163621
2.
Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial.
Blood
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38620072
3.
Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.
Blood
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38620092
4.
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Blood
; 142(11): 961-972, 2023 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37363867
5.
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Blood
; 142(5): 446-459, 2023 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37172204
6.
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 25(6): 744-759, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38821083
7.
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
Blood
; 139(9): 1318-1329, 2022 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35108374
8.
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
Blood
; 139(2): 177-187, 2022 01 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34758069
9.
Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia.
Eur J Haematol
; 112(5): 788-793, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38311570
10.
Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry.
Eur J Haematol
; 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38693677
11.
A Context-based Chatbot Surpasses Trained Radiologists and Generic ChatGPT in Following the ACR Appropriateness Guidelines.
Radiology
; 308(1): e230970, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37489981
12.
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Blood
; 138(19): 1805-1816, 2021 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34086865
13.
MARCKS affects cell motility and response to BTK inhibitors in CLL.
Blood
; 138(7): 544-556, 2021 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33735912
14.
Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group.
Ann Hematol
; 102(11): 3083-3090, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37358640
15.
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
N Engl J Med
; 380(23): 2225-2236, 2019 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31166681
16.
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
Blood
; 135(26): 2402-2412, 2020 06 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32206772
17.
Management of front line chronic lymphocytic leukemia.
Am J Hematol
; 97 Suppl 2: S3-S10, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36125035
18.
[Follow-up II of newborn hearing screening : Evaluation of a follow-up II facility after implementation of newborn hearing screening in Germany]. / Follow-up-II des Neugeborenen-Hörscreenings : Evaluation der Ergebnisqualität einer Follow-up-II-Einrichtung nach Einführung des Neugeborenen-Hörscreenings in Deutschland.
HNO
; 70(3): 179-186, 2022 Mar.
Artigo
em Alemão
| MEDLINE | ID: mdl-34448878
19.
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial.
Haematologica
; 106(2): 543-554, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32107341
20.
Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.
Am J Hematol
; 96(9): 1112-1119, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34050972